2,430 material Form 8-K filings that 2,054 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Corbus reported a third-quarter 2026 net loss of $37.8 million, up from $23.3 million a year earlier, driven by a $15.0 million development milestone under its CSPC license. Net loss per share narrowed to $1.81 from $1.90, but the filing shows a higher share count of 20,837,787 weighted shares. The company had $115.3 million in cash and investments and says it expects this to fund operations into 2028.
Net loss of $37.8 million, or $1.81 per share, for the quarter ended September 30, 2026, versus $23.3 million, or $1.90 per share, a year earlier
Operating expenses rose $14.4 million to $38.8 million, including a $15.0 million development milestone under the CSPC licensing agreement
Cash, cash equivalents and investments totaled $115.3 million at September 30, 2026, which the company expects to fund operations into 2028
TEMPO-1 Phase 3 study of sutantatug envedotin began dosing in September 2026; CANYON-1 Phase 1b topline data for CRB-913 will be presented at ObesityWeek on November 15, 2026
Jerash Holdings (US), Inc. reported fiscal 2027 second-quarter results for the quarter ended September 30, 2026, with revenue up 19.8% and net income of $2.2 million, or $0.16 per diluted share, versus $479,000 a year earlier. The company also guided to fiscal third-quarter revenue of approximately $49 million to $51 million and a gross margin of approximately 16% to 17%.
Q2 revenue rose 19.8% to $50.3 million from $42.0 million; gross margin rose 320 basis points to 18.2%
Operating income was $3.1 million, up from $1.1 million; net income was $2.2 million, or $0.16 per diluted share
Q3 outlook: revenue of approximately $49 million to $51 million and gross margin of approximately 16% to 17%
Board approved a regular quarterly dividend of $0.05 per share on November 5, 2026, payable November 23, 2026 to holders of record as of November 16, 2026
Aviat Networks reported fiscal 2027 first-quarter revenue of $102.0 million, down 5.0% from $107.3 million a year earlier, and a GAAP net loss of $2.8 million, or $0.22 per diluted share, versus net income of $0.2 million a year earlier. The company also updated its full-year fiscal 2027 guidance to revenue of $450 million to $475 million and Adjusted EBITDA of $50.0 million to $55.0 million, but the filing does not give prior guidance figures for comparison.
Q1 revenue $102.0 million vs. $107.3 million a year earlier; GAAP gross margin fell to 29.6% from 33.2%
GAAP net loss of $2.8 million ($0.22 per diluted share) vs. net income of $0.2 million; non-GAAP net income of $1.5 million ($0.12 per share) vs. $5.5 million ($0.43)
Bookings of over $150 million, up 75% year over year; Adjusted EBITDA of $6.0 million vs. $9.1 million
Cash of $55.4 million at October 2, 2026, down from $72.8 million at July 3, 2026; total debt of $85.9 million
Alliance Laundry reported third-quarter 2026 net revenues of $461 million, up 5% from a year earlier, and net income of $65 million compared with $33 million. It raised its full-year 2026 Adjusted EBITDA growth guidance to about 10%, the high end of its prior 8% to 10% range, while keeping revenue growth guidance at 6% to 7%. The company also repurchased $75 million of its common stock during the quarter.
Net revenues were $461 million, up 5% from $438 million; North America revenue rose 8% to $356 million.
Net income was $65 million versus $33 million; diluted EPS was $0.32 versus $0.19.
Adjusted EBITDA rose 14% to $127 million, with a 27.5% margin; a discrete tariff refund benefit helped results.
The company repurchased $75 million of stock and repaid $45 million of debt, reducing net leverage to 2.25x.
HIVE reported revenue of $84.9 million for the quarter ended September 30, 2026, up 7.3% from the prior quarter but down 2.7% from a year earlier. The GAAP net loss widened to $78.7 million from $15.8 million a year earlier, including a $31.2 million non-cash impairment of mining equipment. Shareholders face a mix of sequential improvement, a year-over-year revenue decline and a larger loss.
Revenue $84.9 million, up 7.3% sequentially and down 2.7% year over year; HPC revenue $8.8 million, up 70.7% year over year
GAAP net loss $78.7 million, or $0.29 per share, versus a net loss of $15.8 million in the year-earlier quarter
Non-cash charges included $54.9 million of depreciation and a $31.2 million impairment of mining equipment
Cash and cash equivalents $139.0 million as of September 30, 2026; HIVE targets about $200 million of GPU Cloud ARR by Q4 calendar 2026
Kalaris Therapeutics reported a third-quarter net loss of $11.0 million, down from $11.9 million a year earlier, and $82.9 million in cash and marketable securities as of September 30, 2026. The company said a pilot manufacturer batch failed a release specification, pushing preliminary Phase 1b/2 data for TH103 in neovascular AMD to 2H 2027 and extending its cash runway into 2028.
Net loss was $11.0 million for the quarter ended September 30, 2026, versus $11.9 million a year earlier; net loss per share was $0.46 versus $0.64.
Research and development expenses were $8.3 million, down from $9.1 million; general and administrative expenses were $3.5 million, down from $3.6 million.
Cash, cash equivalents and marketable securities were $82.9 million, down from $118.0 million at December 31, 2025, and are expected to fund operations into 2028.
A new TH103 batch is now expected in Q2 2027, and technology transfer to KBI Biopharma was completed with test batches meeting target specifications.
MasterCraft reported results for the first three months of its transition period ended October 4, 2026, following its May 15, 2026 merger with Marine Products and a change in fiscal year-end to December 31. Net sales, income from continuing operations, and Adjusted EBITDA all rose from the prior-year period, though gross margin fell 120 basis points, largely due to the Marine Products business. The company also gave outlook for the six-month transition period ending December 31, 2026.
Net sales were $154.1 million, up $85.1 million or 123.4%; excluding the Marine Products contribution, sales rose 37.4%, or $25.8 million.
Income from continuing operations was $12.1 million, or $0.50 per diluted share, versus $3.7 million, or $0.22, a year earlier.
Adjusted EBITDA was $20.1 million, a 13.0% margin, compared with $7.0 million and 10.1% in the prior-year period.
For the transition period, the company expects net sales of $293 million to $297 million, Adjusted EBITDA of $32 million to $34 million, and Adjusted EPS of $0.75 to $0.80.
Xilio Therapeutics reported third quarter 2026 results for the period ended September 30, 2026. Collaboration and license revenue fell to $10.0 million from $19.1 million a year earlier, while the net loss narrowed to $5.9 million from $16.3 million, mainly because of a non-cash warrant fair value gain, and operating loss widened. The company says its cash will fund operations into the first quarter of 2028, excluding up to $36.2 million in possible Series C warrant proceeds.
Collaboration and license revenue was $10.0 million, down from $19.1 million in Q3 2025, driven by lower revenue under the AbbVie and Gilead agreements.
Net loss was $5.9 million, or $(0.30) per share, versus $16.3 million, or $(1.58) per share, a year earlier; the change in fair value of warrant liabilities was a $4.8 million gain versus a $15.4 million loss.
Loss from operations was $11.7 million versus $1.9 million a year earlier, as R&D expenses rose to $14.8 million and G&A expenses to $6.9 million.
Cash and cash equivalents were $122.2 million at September 30, 2026, with runway stated into the first quarter of 2028.
Exagen reported third-quarter 2026 revenue of $18.4 million, up 7% from $17.2 million a year earlier, and a net loss of $6.3 million, compared with $7.1 million in the prior-year quarter. The company reiterated its full-year 2026 revenue guidance of $72 million to $75 million, which means results did not change its outlook.
Q3 2026 revenue $18.4 million vs. $17.2 million in Q3 2025; nine-month revenue $55.7 million, up 11%
Q3 2026 net loss $6.3 million vs. $7.1 million; nine-month net loss $13.5 million vs. $15.3 million
Full-year 2026 revenue guidance of $72 million to $75 million reiterated; cash and equivalents $28.1 million at September 30, 2026
Ambiq Micro reported third-quarter 2026 net sales of $38.1 million, up 110% from a year earlier, and a GAAP net loss of $7.1 million, narrowed from $9.0 million in the third quarter of 2025. The company expects fourth-quarter 2026 net sales of $43.5 million to $44.5 million, above the third-quarter level, and cited accelerating edge AI demand. Shareholders are seeing faster sales growth and a smaller loss, though the company used $25.4 million in operating cash over the first nine months of 2026.
Q3 2026 net sales were $38.1 million, up from $18.2 million in Q3 2025; GAAP gross margin was 46.7%.
GAAP net loss was $7.1 million in Q3 2026, compared with $9.0 million a year earlier.
Q4 2026 guidance: net sales of $43.5 million to $44.5 million and non-GAAP net loss per share of ($0.09) to ($0.03).
Cash and cash equivalents were $363.5 million at September 30, 2026, up from $140.3 million at December 31, 2025.
Arbutus reported third-quarter 2026 net income of $59.1 million, driven mainly by a $67.3 million dividend from Genevant, compared with a net loss of $7.7 million a year earlier. Revenue fell to $0.3 million from $0.5 million, and the operating loss widened to $10.5 million from $8.7 million. The company ended the quarter with $337.5 million in cash and investments after returning $230 million to shareholders through a tender offer in early October.
Net income was $59.1 million, or $0.30 per basic and diluted share, for the quarter ended September 30, 2026, versus a net loss of $0.04 per share a year earlier.
Total revenue was $0.3 million, down from $0.5 million, and the operating loss was $10.5 million, compared with $8.7 million.
A $230 million Dutch Auction tender offer completed in early October 2026 bought 46 million shares at $5.00 per share, about 23% of shares outstanding as of September 29, 2026.
The FDA lifted the clinical hold on the AB-101 IND application in October 2026.
Kustom Entertainment reported third-quarter 2026 revenue from continuing operations up 57% to $2.7 million, but a loss from continuing operations of $2,670,888 widened from $994,761 a year earlier. Net income of $2,346,315 was driven by a $5,017,203 gain from discontinued operations tied to the sale of its legacy video solutions business to Cycurion, Inc. For shareholders, the results show revenue growth alongside a larger operating loss, and the pending $TFL acquisition's closing depends on financing and an extended outside date of December 18, 2026.
Service revenue grew 65% to $2.1 million, driven mainly by transaction volume on the TicketSmarter marketplace.
Loss from continuing operations was $2,670,888, or $(5.13) per share, versus $(994,761), or $(86.38) per share, a year earlier; about $625,000 of the increase was non-cash expense.
Net income attributable to common stockholders was $2,346,315, or $4.51 per basic and diluted share, after $5,017,203 of income from discontinued operations.
Stockholders approved the TFL, LLC acquisition on October 5, 2026; the purchase agreement's outside date was extended to December 18, 2026.
Energy Focus reported third quarter 2026 net sales of $4.8 million, up from $0.8 million a year earlier, and net income of $0.5 million, or $0.08 per share, compared with a net loss of $0.2 million in the third quarter of 2025. The company attributed the growth mainly to a Taiwan Uninterruptible Power Supply project with a new customer, and its forward-looking statements still cite substantial doubt about its ability to continue as a going concern.
Q3 2026 net sales were $4.8 million, up 481.2% year over year and up 28.1% from $3.7 million in Q2 2026.
Q3 2026 net income was $0.5 million, or $0.08 per diluted share, versus a Q2 2026 net loss of $0.9 million, or $(0.14) per share.
Nine-month 2026 net loss was $0.5 million, or $(0.08) per share, compared with $0.7 million, or $(0.12) per share, in the same period of 2025.
Cash was $3.3 million at September 30, 2026, including $0.9 million of short-term borrowings proceeds, versus $1.1 million at December 31, 2025.
Cellectar Biosciences reported a third-quarter 2026 net loss of $8.0 million, or $0.46 per share, up from $4.4 million, or $1.41 per share, a year earlier. Research and development expenses rose to $5.4 million from $2.5 million, tied to the start of its Phase 3 confirmatory trial and its CLR 125 Phase 1b trial. The company said its September 30, 2026 cash balance is adequate to fund budgeted operations into the second quarter of 2027.
Q3 2026 net loss was $8.0 million, or $0.46 per share, versus $4.4 million, or $1.41 per share, in Q3 2025.
R&D expenses were about $5.4 million versus about $2.5 million a year earlier; G&A expenses were about $2.7 million versus $2.3 million.
Cash and cash equivalents were $24.6 million at September 30, 2026, including net proceeds of about $31.7 million from a May 2026 offering.
The company plans to dose the first patient in its Phase 3 confirmatory trial in Q1 2027 and submit an NDA seeking accelerated approval in 1H 2027.
CalciMedica reported third-quarter 2026 results, with a net loss of $1.7 million, or $0.24 per share, versus a net loss of $7.8 million, or $2.59 per share, a year earlier. The improvement was driven mainly by a noncash $3.1 million gain in other income, while operating expenses fell, and the filing reports cash of $13.8 million as of September 30, 2026, which the company expects to fund its operating plan into the second half of 2027.
Q3 2026 net loss was $1.7 million ($0.24 per share), compared with $7.8 million ($2.59 per share) in Q3 2025.
Q3 2026 total other income was $3.1 million, mainly from a noncash change in fair value of financial instruments.
Q3 2026 research and development expenses were $2.3 million, down from $3.9 million, and general and administrative expenses were $2.4 million, up from $1.8 million.
Cash, cash equivalents and short-term investments were $13.8 million as of September 30, 2026.
LENSAR reported third quarter 2026 results for the quarter ended September 30, 2026. Total revenue fell 1% year over year to $14.1 million, as lower system sales outweighed 17% growth in recurring revenue, and the net loss widened to $4.7 million from $3.7 million. Adjusted EBITDA improved to $1.7 million from a $0.3 million loss a year earlier.
Total revenue was $14.1 million versus $14.3 million a year earlier; recurring revenue rose 17% to $12.6 million and was 89% of revenue.
Net loss was $4.7 million, compared with $3.7 million in the prior-year quarter; adjusted EBITDA was $1.7 million versus a $0.3 million loss.
The company placed 10 ALLY systems in the quarter, ending with 225 ALLY systems installed and a backlog of 12 systems as of September 30, 2026.
Cash, cash equivalents and investments totaled $12.6 million at September 30, 2026, compared with $18.0 million at December 31, 2025.
Hemab Therapeutics reported a third-quarter 2026 net loss of $27.3 million, up from $17.1 million a year earlier, as research and development and general and administrative expenses rose. Net loss per share improved to $0.58 from $18.04, but the company attributes that change mainly to a larger weighted-average share count after its initial public offering and preferred stock conversion. The company said its cash, cash equivalents and marketable securities of $430.2 million will fund operations into 2029, and it started the Phase 3 SOLARA trial of sutacimig in Glanzmann thrombasthenia.
Net loss was $27.3 million, or $0.58 per share, for the quarter ended September 30, 2026, versus $17.1 million, or $18.04 per share, a year earlier
Research and development expenses were $24.6 million, up from $14.6 million; general and administrative expenses were $5.1 million, up from $2.5 million
Cash, cash equivalents and marketable securities were $430.2 million at September 30, 2026, versus $457.5 million at June 30, 2026, with runway stated as into 2029
Phase 3 SOLARA trial of sutacimig in Glanzmann thrombasthenia was initiated, with first participants scheduled to enter the run-in period in the fourth quarter of 2026
Palladyne AI reported third-quarter 2026 revenue of $8.6 million, up from $0.9 million a year earlier, and raised the low end of its full-year 2026 revenue guidance to $25.0 million while keeping the top end at $27.0 million. The GAAP net loss widened to $12.0 million, or $0.25 per share, from $3.7 million, or $0.09 per share, in the prior-year quarter. Shareholders also face a 9% reduction in fully diluted shares after warrants and contingent shares expired on September 24, 2026.
Q3 2026 revenue was $8.6 million versus $0.9 million in Q3 2025, and up 48% sequentially.
GAAP net loss was $12.0 million ($0.25 per share) versus $3.7 million ($0.09 per share) a year earlier.
Full-year 2026 revenue guidance is now $25.0 million to $27.0 million, up from a prior low end, and backlog was $18.7 million as of September 30, 2026.
All 20.5 million warrants and 2.3 million remaining contingent merger consideration shares expired on September 24, 2026; cash, equivalents and marketable securities were $47.0 million.
Cullinan Therapeutics reported third quarter 2026 results, with a net loss of $49.4 million, down from $50.6 million a year earlier, as research and development and general and administrative expenses both declined. The company said its cash and investments of $313.8 million as of September 30, 2026 provide runway into 2029 under its current operating plan, though cash was down from $439.0 million at December 31, 2025.
Q3 2026 net loss was $49.4 million, compared with $50.6 million in Q3 2025; nine-month net loss was $152.8 million, compared with $169.2 million
Q3 2026 research and development expenses were $40.2 million, versus $42.0 million a year earlier
Cash, cash equivalents, investments, and interest receivable were $313.8 million at September 30, 2026, versus $439.0 million at December 31, 2025, with runway into 2029
Sionna Therapeutics reported a third-quarter 2026 net loss of $32.4 million, up from $20.3 million a year earlier, as research and development and general and administrative expenses rose. The company cut its workforce by about 46% in September 2026 and is not advancing SION-719 after its PreciSION CF Phase 2a trial missed its key activity endpoint, focusing instead on SION-451 + SION-2222, with a Phase 2 trial planned for the first quarter of 2027. Cash, cash equivalents and marketable securities were $249.8 million at September 30, 2026, which the company expects to fund operations into the second half of 2029.
Net loss was $32.4 million, or $0.72 per share, for the quarter ended September 30, 2026, compared with $20.3 million, or $0.46 per share, a year earlier.
R&D expenses were $22.0 million and G&A expenses were $12.8 million, up from $16.0 million and $7.8 million in the prior-year quarter.
Cash, cash equivalents and marketable securities totaled $249.8 million, down from $310.3 million at December 31, 2025.
The AscenSION CF Phase 2 proof-of-concept trial of SION-451 + SION-2222 is expected to start in the first quarter of 2027.
Upstream Bio reported a third-quarter 2026 net loss of $41.2 million, up from $33.7 million a year earlier, as research and development and general and administrative expenses rose and collaboration revenue fell to $395,000 from $683,000. The company had $207.4 million in cash, cash equivalents and short-term investments at September 30, 2026, which it expects to fund planned operations through 2027, and it plans to start Phase 3 trials of verekitug in severe asthma and CRSwNP in the first quarter of 2027.
Q3 2026 net loss was $41.2 million, compared with $33.7 million in Q3 2025.
Research and development expenses were $36.6 million, up $3.6 million from $33.0 million a year earlier.
General and administrative expenses were $7.2 million, up $1.7 million from $5.5 million.
Cash, cash equivalents and short-term investments totaled $207.4 million as of September 30, 2026.
908 Devices reported third-quarter 2026 revenue of $19.0 million, up 35% from a year earlier, and a net loss from continuing operations of $4.6 million, down from $14.9 million. The company raised the low end of its full-year 2026 revenue guidance to $68.5 million to $70.0 million. A $11.0 million noncash reduction in contingent consideration expense helped narrow the loss, and the company reported no debt outstanding.
Q3 2026 revenue was $19.0 million, up from $14.0 million a year earlier; GAAP gross margin was 53%, unchanged from the prior year.
Operating expenses fell to $15.5 million from $23.7 million, mainly due to an $11.0 million noncash reduction in contingent consideration expense.
2026 revenue guidance is now $68.5 million to $70.0 million, up from $68.0 million to $70.0 million at the low end.
Cash and marketable securities were $99.1 million as of September 30, 2026, with no debt outstanding.
Olema Pharmaceuticals reported a wider third-quarter 2026 net loss of $73.6 million, or $0.73 per share, versus $42.2 million, or $0.49 per share, a year earlier. The filing shows higher research and development and general and administrative spending tied to its Phase 3 trials and early preparations for a possible launch of palazestrant. Shareholders face a higher cash burn, with $413.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026.
Net loss was $73.6 million for the quarter ended September 30, 2026, compared with $42.2 million a year earlier.
GAAP research and development expenses rose to $67.6 million from $40.0 million; G&A expenses rose to $9.9 million from $5.9 million.
Cash, cash equivalents, and marketable securities were $413.8 million at September 30, 2026.
The company expects top-line data from the Phase 3 OPERA-01 trial in the first quarter of 2027 and appointed Jason O'Byrne as Chief Financial Officer.
Humacyte reported third-quarter 2026 results with Symvess sales of $1.0 million, up from $0.4 million in the second quarter and $0.7 million a year earlier. The quarterly net loss narrowed to $15.5 million, or $0.06 per share, from $17.5 million, or $0.11 per share, a year earlier, but the nine-month net loss widened to $70.0 million, mainly due to a non-cash remeasurement of the contingent earnout liability.
Q3 2026 Symvess sales were $1.0 million, versus $0.4 million in Q2 2026 and $0.7 million in Q3 2025.
Q3 2026 net loss was $15.5 million ($0.06 per share), compared with $17.5 million ($0.11 per share) in Q3 2025.
Nine-month 2026 net loss was $70.0 million, versus $16.0 million in the prior-year period, driven by a non-cash earnout remeasurement.
October 2026 Symvess sales were $0.8 million; cash and equivalents were $64.9 million as of September 30, 2026.
Ovid Therapeutics reported third quarter 2026 results with no revenue, compared with $132 thousand a year earlier. The net loss widened to $20.8 million from $12.2 million, driven by research and development expenses that rose to $15.7 million from $5.9 million as the OV329 and OV4071 programs advanced. The company said its cash runway extends into 2029, though its net loss per share improved to $0.10 from $0.17 mainly because the weighted-average share count rose to about 203 million from about 71 million.
Net loss was $20.8 million for the quarter ended September 30, 2026, versus $12.2 million a year earlier.
Research and development expenses were $15.7 million, compared with $5.9 million in the prior-year quarter.
Cash, cash equivalents and marketable securities were $161.4 million at September 30, 2026, up from $90.4 million at December 31, 2025, with runway expected into 2029.
Topline data for OV329 photosensitivity study and OV4071 Phase 1 study are expected in the first quarter of 2027.
Opus Genetics reported a third-quarter 2026 net loss of $46.5 million, or $0.46 per share, up from $17.5 million, or $0.25 per share, a year earlier. License and collaborations revenue fell to $1.1 million from $3.1 million, while research and development expense more than doubled to $14.5 million, so shareholders face a larger loss per share with less revenue. The company said its cash of $89.0 million as of September 30, 2026, plus potential future funding under its Oberland note purchase agreement, should fund operations into 2029.
Net loss of $46.5 million, or $0.46 per share, versus $17.5 million, or $0.25 per share, in Q3 2025.
License and collaborations revenue of $1.1 million versus $3.1 million; R&D expense of $14.5 million versus $6.4 million.
Fair value change in instruments measured at fair value was a $28.6 million charge in the quarter.
Cash and cash equivalents of $89.0 million as of September 30, 2026; company expects cash to fund operations into 2029.
D-Wave Quantum reported third-quarter 2026 revenue of $4.5 million, up 21% from a year earlier, and a net loss of $48.2 million, or $0.13 per share, versus $139,986 thousand a year earlier. The net loss improvement mainly reflects a $121.9 million smaller non-cash warrant remeasurement charge, while adjusted EBITDA loss widened to $37.7 million and GAAP operating expenses rose 84%. Quarterly bookings fell 19%, though nine-month bookings were $37.4 million, and the company stated it had $503.4 million in cash and marketable securities.
Q3 2026 revenue was $4.5 million, up 21% year over year; GAAP gross margin fell to 52.9%
Net loss was $48.2 million ($0.13 per share), down $91.8 million year over year, driven mainly by the absence of a $121.9 million warrant remeasurement charge
Adjusted EBITDA loss was $37.7 million, up 83% year over year, as operating expenses rose to support product development and go-to-market efforts
Q3 bookings were $1.9 million, down 19%; nine-month bookings were $37.4 million, up 611%
Liquidia reported a third-quarter 2026 net loss of $236.3 million, or $2.64 per share, after a $389.7 million litigation settlement charge tied to its global settlement with United Therapeutics. Net product sales of YUTREPIA rose to $222.7 million from $51.7 million a year earlier, and non-GAAP adjusted EBITDA was $140.5 million. The settlement resolves all pending litigation with United Therapeutics, and Liquidia agreed to pay net $380.7 million in installments in 2026 and 2027.
Q3 2026 net loss of $236.3 million, or $2.64 per share, versus a net loss of $3.5 million, or $0.04 per share, in Q3 2025
Net product sales of $222.7 million, up 31% from Q2 2026 and up from $51.7 million in Q3 2025
Adjusted EBITDA of $140.5 million, the fifth consecutive quarterly increase; cash and cash equivalents were $396.1 million before settlement payments
Global settlement with United Therapeutics dated October 13, 2026, with Liquidia agreeing to pay net $380.7 million in 2026 and 2027
Chicago Atlantic Real Estate Finance reported third quarter 2026 results, with diluted distributable earnings of $0.49 per share, equal to the year-earlier figure and up from $0.43 in the second quarter. GAAP net income fell to $6.4 million, or $0.25 per share, from $8.9 million, or $0.42 per share, a year earlier, as net interest income and credit loss provisions weighed on results. The company's pending merger into Chicago Atlantic BDC and its dividend outlook remain key factors for shareholders.
Diluted distributable earnings were $0.49 per share for the quarter ended September 30, 2026, compared with $0.49 a year earlier and $0.43 in the June 30, 2026 quarter.
GAAP net income was $6.4 million ($0.25 per diluted share), down from $8.9 million in the year-earlier quarter; net interest income was $12.5 million versus $13.7 million.
Provision for current expected credit losses was $2.8 million, compared with $0.6 million a year earlier.
Distributable earnings now include Koach Note income beginning in the third quarter of 2026, a definitional change the company says has no impact on prior-period comparisons; the company expects a 2026 dividend payout of 90% to 100% of dist
Harvard Bioscience reported third quarter 2026 revenue of $22.2 million, up from $20.6 million a year earlier, but its net loss widened to $2.6 million from $1.2 million and adjusted EBITDA fell to $1.8 million from $2.0 million. The company reaffirmed its full-year 2026 revenue growth guidance of 3% to 5% and updated its full-year adjusted EBITDA target to growth of (1%) to 4%.
Q3 2026 revenue was $22.2 million, up 7.8% from $20.6 million in Q3 2025.
Q3 2026 net loss was $2.6 million, or $(0.58) per share, versus a net loss of $1.2 million in Q3 2025.
Q3 2026 adjusted EBITDA was $1.8 million, versus $2.0 million a year earlier.
Full-year 2026 guidance: revenue growth of 3% to 5%, adjusted gross margin of 57% to 59%, and adjusted EBITDA growth of (1%) to 4%.
Protalix reported third-quarter 2026 total revenue of $21.9 million, up from $17.9 million a year earlier, and net income of $4.0 million, or $0.05 per share, compared with $2.4 million, or $0.03 per share. Nine-month revenue reached $75.6 million versus $43.6 million, and the company reaffirmed 2026 total revenue guidance of $78.0 million to $83.0 million, which includes a $25.0 million Chiesi milestone received in the first quarter. For shareholders, revenue and profit rose year over year, cash and short-term deposits totaled $48.5 million at September 30, 2026, and the company reported no outstanding debt or warrants.
Q3 2026 net income was $4.0 million ($0.05 per share, basic and diluted) versus $2.4 million ($0.03 per share) in Q3 2025
Nine-month 2026 total revenue was $75.6 million versus $43.6 million, including a $25.0 million Chiesi milestone received in Q1 2026
2026 total revenue guidance of $78.0 million to $83.0 million was reaffirmed, with the company expecting to meet or exceed these ranges
Cash, cash equivalents and short-term bank deposits were $48.5 million at September 30, 2026; the company has no outstanding debt or warrants
Sally Beauty Holdings reported fourth-quarter fiscal 2026 results for the period ended September 30, 2026, with net sales of $953 million, up 0.6%, and GAAP diluted earnings per share of $0.60, up 22%. The company also issued initial fiscal 2027 guidance calling for adjusted diluted EPS of $2.20 to $2.30, compared with $2.08 in fiscal 2026. The guidance is an initial forecast rather than a revision, and it points to higher sales and adjusted earnings per share in fiscal 2027.
Q4 net sales were $953 million, up 0.6%; consolidated comparable sales rose 0.9%.
Q4 GAAP diluted EPS was $0.60, up 22%; adjusted diluted EPS was $0.62, up 13%.
Fiscal 2027 guidance: net sales of $3.77 billion to $3.81 billion and adjusted diluted EPS of $2.20 to $2.30.
Full-year cash flow from operations was $323 million; the company repurchased $113 million of shares during fiscal 2026.
TransDigm reported fourth-quarter fiscal 2026 net sales of $2,988 million, up 23%, and EPS of $10.33, up 33%, while quarterly net income fell 4% to $586 million on higher interest and tax expense. The company also issued fiscal 2027 guidance calling for net sales of $11,950 million to $12,150 million and EPS of $42.06 to $42.91, which shareholders can compare against the fiscal 2026 results.
Q4 net sales $2,988 million, up 23% from $2,437 million; EPS $10.33, up 33% from $7.75.
Q4 net income $586 million, down $23 million or 4%; adjusted EPS $12.44, up 15% from $10.82.
Fiscal 2027 guidance: net sales $11,950 million to $12,150 million; EPS $42.06 to $42.91; adjusted EPS $47.09 to $47.94.
Company returned $943 million through buybacks in Q4 and $2.8 billion for fiscal 2026.
Sono Group reported third-quarter 2026 net income of $0.6 million, compared with a net loss of $1.4 million in the third quarter of 2025, driven mainly by Bitcoin treasury income and a non-cash fair-value gain. For the first nine months, the company reported a net loss of $5.1 million, versus net income of $7.4 million a year earlier that included a $12.4 million fair-value gain, and management disclosed substantial doubt about its ability to continue as a going concern. Shareholders will vote on a proposed redomiciliation to Delaware at a meeting on December 11, 2026.
Q3 2026 net income was $0.6 million, versus a net loss of $1.4 million in Q3 2025; basic EPS was $0.32.
Nine-month 2026 net loss was $5.1 million, compared with net income of $7.4 million in the prior-year period.
General and administrative expenses fell 24% to $0.6 million in Q3 2026.
At September 30, 2026, cash was $0.5 million, Bitcoin was valued at $4.4 million, and $5.05 million of convertible debentures were outstanding, maturing January to April 2027.
Ampco-Pittsburgh reported third quarter 2026 net sales of $111.7 million, up 3% from $108.0 million a year earlier, and net income attributable to the company of $0.5 million, or $0.02 per share, compared with a net loss of $2.2 million, or $0.11 per share, in the prior-year quarter. The company also reduced net debt by $19.5 million in the quarter, to $111.0 million, which strengthens its balance sheet for shareholders.
Net sales were $111.7 million, versus $108.0 million in the third quarter of 2025; Air and Liquid Processing sales rose 17% to $42.8 million
Net income attributable to Ampco-Pittsburgh was $0.5 million, or $0.02 per share, versus a net loss of $2.2 million, or $0.11 per share, a year earlier
Adjusted EBITDA rose 2% to $9.4 million; adjusted EBITDA margin was 8.4%, compared with 8.5% in the prior-year period
Net debt fell to $111.0 million at September 30, 2026, down $19.5 million from $130.5 million at June 30, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.